BioAge Labs is testing BGE-102, an oral NLRP3 inhibitor, in a Phase 2 trial designed to reduce high-sensitivity C-reactive protein (hsCRP) and cardiovascular risk in 160 adults. Phase 1 data showed median hsCRP reductions of 86% at selected doses, establishing a potential therapeutic approach to systemic inflammation-driven cardiac disease.
Key Points
- NLRP3 inhibition reduces hsCRP by 86% in Phase 1 participants
- 12-week Phase 2 trial tests three dose levels against placebo
- Drug is orally available and crosses the blood-brain barrier
Longevity Analysis
Chronic systemic inflammation accelerates cardiovascular aging and remains a major contributor to mortality across multiple physiological pathways. The 86% reduction in hsCRP observed in Phase 1 suggests that targeted modulation of NLRP3 inflammasome activation may suppress a central driver of atherosclerotic progression and endothelial dysfunction. Reducing elevated inflammatory markers in middle-aged and older adults with existing risk factors addresses one of the most tractable mechanisms of age-related cardiac disease, provided efficacy and safety are confirmed in Phase 2 and sustained in longer-term follow-up.
Original published by LT Wire.